testosterone enanthate

Warnings	Classification	Alternate Names
hazardous drug group 2	androgen, hormonal agent	DELATESTRYL

Indications

- breast cancer, (for all oncological indications see BC Cancer benefit drug list)
- male hypogonadism and hormone therapy for transgender males
- **This monograph is specific for** testosterone **enanthate (DELATESTRYL)** only

Reconstitution and Stability

- Prepared by pharmacy in a biological safety cabinet (BSC). See approved safe work procedures for preparation outside of a BSC.
- store at room temperature

Compatibility

Preparation and Administration

- **VCH** – Refer to Hazardous Drugs – Education and Safety Requirements
- **PHC** – Refer to Site Specific Restrictions for required competencies to administer this drug and where the drug can be administered. Refer to Hazardous Drugs for handling and waste disposal

Administration Route	Approved	Preparation and Administration Instructions	Required Monitoring
Subcutaneous	YES	*hormone therapy for transgender males*: maximum of 100 mg rotate injection sites	Basic monitoring
Intramuscular	YES	deeply into the gluteal muscle	Basic monitoring or according to protocol
IV direct	NO		
IV intermittent	NO		
Continuous IV infusion	NO		

testosterone enanthate

Dosage

- oncological indications: **follow specific protocol**; dose and schedule depend on protocol and patient response.
  - Metastatic breast cancer: 400 mg IM for one dose on day 1 every 4 weeks
  - Refer to BC Cancer Drug Manual Monographs

- male hypogonadism = 50 mg to 100 mg IM once weekly or 100 mg to 200 mg IM every 2 weeks

- hormone therapy for transgender males: 100 mg to 200 mg IM every 2 weeks or 50 mg to 100 mg IM/subcutaneous every week
  - may adjust dose after 3 months based on clinical response and serum testosterone levels

Potential Hazards of Parenteral Administration

- injection site pain, urticaria, injection reactions (including induration and furunculosis)

Important Implications

Contraindications/Cautions

- should not be administered to those with known hypersensitivity to any component. Each mL contains: testosterone (synthesized from soy) enanthate 200 mg formulated in sesame oil with 0.5% chlorobutanol as preservative
- in diabetic patients, the metabolic effects of androgens may decrease blood glucose. Therefore, insulin or oral hypoglycemic requirements may change
- May potentiate the effects of oral anticoagulants

- Pregnancy/Lactation: refer to Lexicomp or Micromedex

Side effects

- virilization in women (e.g., voice changes, clitoromegaly)
- worsening of hypercalcemia
- worsening of tumour growth during initial therapy